Jc polyomavirus vlp (virus-like particle) with a targeting peptide
AssigneeLife Science Inkubator GmbH
InventorsSEBASTIAN FRANKEN, ALEXANDER GLASSMANN, NADINE TEMME
Life of this patent
Estimating the term…
Loading patent…
AssigneeLife Science Inkubator GmbH
InventorsSEBASTIAN FRANKEN, ALEXANDER GLASSMANN, NADINE TEMME
Estimating the term…
The disclosure relates to a fusion protein comprising at least a first and a second peptide, wherein —the second peptide comprises a targeting region and a first and a second interaction region, —the second peptide is located on the surface of the fusion protein; —the second peptide comprises at least two interaction pairs, wherein an interaction pair is formed by an amino acid of the first interaction region and an amino acid of the second interaction region, —the interaction between the amino acids of an interaction pair is covalent or non-covalent; and —at least one interaction pair is a covalent interaction pair in which the amino acids are covalently bound, and to virus like particles (VLP) comprising the fusion protein for use as drug delivery system. Also provided are polynucleotides encoding the fusion protein, suitable expression vectors, host cells, production methods for the fusion protein and the VLP comprising the fusion protein.
A fusion protein comprising at least a first and a second peptide, wherein
The fusion protein according to any of the preceding claims, wherein at least two interaction pairs are non-covalent interaction pairs in which the amino acids interact non-covalently.
The fusion protein according to any of the preceding claims, wherein the number of amino acids in the first and/or second interaction region between the at least one covalent interaction pair the closest non-covalent interaction pair is in the range from 1 to 6 preferably 1 to 4, more preferably 2.
The fusion protein according to any of the preceding claims, wherein the amino acid sequence of the targeting region is selected from the group consisting of Lyp-1, RGD, RGR, HER-2 binding peptide, CREKA peptide, NGR peptide CPP-2, CPP-44, F3, RMS-P3, F56, LTVSPWY-peptide, and WNLPWYYSVSPT-peptide.
Dependencies are inferred from the claim text.